IMM Stock Overview
A late-stage biotechnology company, engages in developing novel LAG-3 related immunotherapies for cancer and autoimmune diseases in Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Immutep Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.28 |
| 52 Week High | AU$0.48 |
| 52 Week Low | AU$0.23 |
| Beta | 1.92 |
| 11 Month Change | -5.79% |
| 3 Month Change | -22.45% |
| 1 Year Change | -1.72% |
| 33 Year Change | -43.56% |
| 5 Year Change | 16.33% |
| Change since IPO | -20.83% |
Recent News & Updates
Recent updates
Shareholder Returns
| IMM | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | -14.9% | -3.6% | 1.5% |
| 1Y | -1.7% | 10.0% | 17.2% |
Return vs Industry: IMM underperformed the Australian Biotechs industry which returned 10% over the past year.
Return vs Market: IMM underperformed the Australian Market which returned 17.2% over the past year.
Price Volatility
| IMM volatility | |
|---|---|
| IMM Average Weekly Movement | 7.5% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 8.6% |
| 10% most volatile stocks in AU Market | 17.3% |
| 10% least volatile stocks in AU Market | 3.4% |
Stable Share Price: IMM has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: IMM's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | n/a | Marc Voigt | www.immutep.com |
Immutep Limited, a late-stage biotechnology company, engages in developing novel LAG-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alpha (efti or IMP321), a soluble LAG-3lg fusion based, which is in clinical development for the treatment of different types of cancers. The company’s product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma.
Immutep Limited Fundamentals Summary
| IMM fundamental statistics | |
|---|---|
| Market cap | AU$414.55m |
| Earnings (TTM) | -AU$42.72m |
| Revenue (TTM) | AU$3.84m |
107.9x
P/S Ratio-9.7x
P/E RatioIs IMM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IMM income statement (TTM) | |
|---|---|
| Revenue | AU$3.84m |
| Cost of Revenue | AU$41.55m |
| Gross Profit | -AU$37.70m |
| Other Expenses | AU$5.01m |
| Earnings | -AU$42.72m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.029 |
| Gross Margin | -981.42% |
| Net Profit Margin | -1,111.87% |
| Debt/Equity Ratio | 0.5% |
How did IMM perform over the long term?
See historical performance and comparison